resistance. In these group 83 (83.8%) were fluoroquinolone resistant. In addition to 129 E coli strains were examined for ESBL producing and ESBL positivity was found in 67 (51,9%) of these strains. When the risk factors regarding the infection caused by ESBL producing or quinolon resistant E coli strains were examined, the use of quinolones in the last 6 months and a history of hospitalization in the last 30 days were found to be significant ( p = 0,00, p = 0,021 and p = 0,034, p = 0,041 respectively) Conclusion. We found that while fluoroquinolone prophylaxis started before TRUS-guided prostate biopsy is still effective in preventing infectious complications that might develop after biopsy, fluoroquinolone-resistant or ESBLproducing E coli strains might be a common microorganism in patients with this kind of complication. This study examined various risk factors for the development of infection in both ESBL-producing strains and strains that developed resistance to fluoroquinolones. Among these factors, a history of the use of fluoroquinolones in the last 6 months and hospitalization in the last one month were found to be significant.
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